神经妥乐平治疗糖尿病神经病变的多中心研究

目的评价神经妥乐平治疗2型糖尿病周围神经病变的疗效及安全性。方法上海地区4家医院的95例糖尿病神经病变患者入选本研究,并随机进入神经妥乐平组(49例)和弥可保组(46例)。神经妥乐平组每天1次静脉推注神经妥乐平针剂,每次2支(3．6U／支);2周后121服神经妥乐平片,每次2片(4．0U／片),每天2次,共2周。弥可保组每天1次肌肉注射弥可保针剂,每次1支;2周后口服弥可保片剂,每次1片,每天3次,共2周。结果经4周治疗后,2组的痛觉VAS评分皆有明显降低,神经妥乐平组治疗1周时的有效率(显著改善 改善)为67．3％、显著改善率为10．2％,均明显高于弥可保组(有效率为34．8％,显著改善率为2．2％)。至4周时,2组的有效率分别为87．0％和68．5％。神经妥乐平组麻木症状改善有效率为58．7％,弥可保组为69．5％,神经妥乐平组显效率(23．9％)明显高于弥可保组(13．0％)。结论神经妥乐平对2型糖尿病神经损害的自发性疼痛、麻木有较好疗效,尤其对疼痛的疗效优于弥可保组。

Multicenter, randomized, positive-controlled clinical study for the effects of nerotropin on diabetic neuropathy

Objective To estimate the effects of Neurotropin in the treatment of neuralgia and numbness in type 2 diabetes mellitus patients with diabetic peripheral neuropathy (DPN), and compare with Methycobal Methods Ninty five patients with DPN from 4 hospitals in shanghai were randomly assigned to two groups:49 cases in Neurotropin group ( 6 ml, IV, QD for 2 weeks, then, 2 tablets, BID for another 2 weeks) 46 cases in Methycobal group( 1 ml, IM, QD for 2 weeks, then, 1 tablet TID for another 2 weeks Results Neurotropin significantly improved neuralgia in type 2 diabetes mellitus with DPN, the efficacy rate was 67 3% in the first week, and 87 0% in the 4th week, comparing with 34 8% and 68 5% in the control group The efficacy rate for numbness was 58 7% in the study group after 4 weeks therapy, and 69 5% in control group In the whole 4 weeks therapeutic course, neuralgia and numbness were improved in the two groups, and the improved rate in Neurotropin group is high than in the control group( P <0 01) Conclusion Neurotropin had good effects in the treatment of diabetic neuralgia and numbness , the efficacy of Neurotropin in improving the senses of neuralgia is better than Methecobal , and similar with Methecobal in treating numbness